👉 In 2026, LAAC has shifted from a “competing therapy” to a patient-specific alternative, with outcomes highly dependent on baseline bleeding risk and clinical context.
f, 74, BMI 23, resistant systolic hypertension, 200 on Telmisartan 80, HCTZ 25 and amlodipine 5.
Added Spironolactone 25 mg, patient nearly fainted next day!
Now on monotherapy Aldactone 25 for second week, what is this?
Symptomatic individuals with no coronary artery calcium but elevated LDL-C have a higher risk of noncalcified plaque and future coronary heart disease events, especially among those aged ≤45 years.
Learn more: https://t.co/uauwGbQwwK #CHD#cvLipids
Understanding of the genetic basis of CV diseases and advances in the technology of therapeutics have led to the development of novel nucleic acid–based therapies. A report from the ESC Cardiovascular Roundtable.
https://t.co/YEiIapyOBw
#cardiotwitter, @ESC_Journals, @escardio
🧵Excellent OCT study on single-shot #PFA for CTI & mitral lines! Despite preemptive #nitroglycerine use, coronary spasm was pretty common!!!
🟩3-months post PFA: vascular wall thickness⬆️by 10% while lumen narrowed⬇️by 17%.
🟩Though NTG was successful in prevention acute vasospasm, coronary stenosis at 3-month with CTI PFA was substantial!
#Epeeps #cardiotwitter
1/13
#Stroke in young patients (<50) is rare but rising. Unlike older adults, strokes here often stem from uncommon causes—not atherosclerosis. Here’s a breakdown clinicians must know.
#NeuroTwitter#MedTwitter
⚠️🧠
Approximately 30% of patients who undergo cardiac surgery develop acute kidney injury. Here are some mechanisms as to why it happens. 🎩 tip to the authors.
https://t.co/Sfr6vCnEaM